Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive ...

Adaptive Biotechnologies plans to release its complete fourth quarter and full year 2025 financial results during its earnings call in February 2026. 1 Excludes Digital Biotechnologies, Inc. cash and ...

Adaptive Biotechnologies (ADPT) has drawn investor attention recently, with the share price at $18.07 and contrasting return numbers over the past year, month and past 3 months raising fresh questions ...

Adaptive shares are trading higher on possible continued momentum after the company announced preliminary fourth-quarter and ...

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) surged around 16% in premarket trading on Monday after the ...

Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers ...

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment of ...

The move will dilute the Seattle company's ownership in the subsidiary from 70% to less than 50%, according to the filing.

Shares of Adaptive Biotechnologies climbed after the company reported preliminary fourth-quarter and full-year results. The stock rose 14% to $18 in premarket trading Monday. Through Friday's close, ...

Adaptive Biotechnologies (ADPT) reported preliminary revenue of ~$72M for Q4 2025, vs estimate of $59.4M and  revenue of $277M for full-year 2025 vs estimate of $264.7M. The company reported cash, ...

Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive ...

SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...